The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: Adaptation of INNOVATE to Sweden

Current Medical Research and Opinion

Volumn 22, Issue 9, 2006, Pages 1765-1776

  Dewilde, Sarah ^a   Turk, F ^b   Tambour, M ^c   Sandstrom T ^d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Novartis Pharma AG   (Switzerland)

^c Novartis Institutes of BioMedical Research   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti IgE; Asthma; Cost effectiveness; Omalizumab

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB;

ADD ON THERAPY; ADULT; ALLERGIC ASTHMA; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE EXACERBATION; FEMALE; HEALTH CARE COST; HUMAN; MALE; MORTALITY; QUALITY OF LIFE; RISK FACTOR; STEADY STATE; SWEDEN;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; DOUBLE-BLIND METHOD; DRUG COSTS; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; PLACEBOS; SWEDEN;

EID: 33749040291     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X132389     Document Type: Article

References (52)

1. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 Step 4 treatment): INNOVATE. Allergy 2005a;60:309-16
2. Tough SC, Hessel PA, Ruff M, et al. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35:657-65
3. Turner MO, Noertjojo K, Vedal S, et al. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998;157:1804-9
4. Weber EJ, Silverman RA, Callaham ML, et al. A prospective multicenter study of factors associated with hospital admission among adults with acute asthma. Am J Med 2002;113: 371-8
5. Hartert TV, Speroff T, Togias A, et al. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol 2002;89:467-73
6. Pollack Jr CV, Pollack ES, Baren JM, et al. A prospective multicenter study of patient factors associated with hospital admission from the emergency department among children with acute asthma. Arch Pediatr Adolesc Med 2002;156: 934-40
7. Sidebotham HJ, Roche WR. Asthma deaths; persistent and preventable mortality. Histopathology 2003;43:105-17
8. Jalaludin BB, Smith MA, Chey T, et al. Risk factors for asthma deaths: a population-based, case-control study. Aust New Zealand J Public Health 1999;23:595-600
9. Lee P, Abisheganaden J, Chee CB, Wang YT. A new asthma severity index: a predictor of near-fatal asthma? Eur Respir J 2001;18:272-8
10. Burr ML, Davies BH, Hoare A, et al. A confidential inquiry into asthma deaths in Wales. Thorax 1999;54:985-9
11. Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998;12: 1322-6
12. Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004;23:723-9
13. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636-42
14. Turk F, Kay S, Higgins V. The economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational study. Poster presented at the British Thoracic Society Meeting, 7-9 December 2005; London (UK)
15. Turk F, Piercy J, Benford M. The human impact of severe persistent allergic asthma: results from a multinational study. Poster presented at the ISPOR 8th Annual European Congress, 6-8 November 2005; Florence(Italy)
16. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90
17. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61
18. Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701-8
19. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-17
20. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-8
21. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34: 632-8
22. Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20:1088-94
23. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111:278-84
24. Holgate S, Bousquet J, Wenzel S, et al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17:233-40
25. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111: 87-90
26. Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). Decided on 24 April 2003 [online]. Available from http://www.lfn.se/upload/English/ ENG_lfnar2003-eng.pdf [last accessed 22 February 2006]
27. Ayre G, Fox H, Chen H, et al. Evaluating response to omalizumab (anti-IgE) in clinical practice. Poster presented at the European Respiratory Society Meeting, 17-21 September 2005; Copenhagen
28. Humbert M, Fox H, Hedgecock S, et al. Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis. Poster presented at European Respiratory Society Meeting, 17-21 September 2005; Copenhagen
29. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341-64
30. Lowhagen O, Ekstrom L, Holmberg S, et al. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243-7
31. Tsuchiya A, Brazier J, McColl E, Parkin D. Deriving preference-based single indices from non-preference-based condition-specific instruments: converting AQLQ into EQ-5D indices. Sheffield (UK): ScHARR, University of Sheffield; 2002
32. Young TA, Yang Y, Brazier J, Tsuchiya A. Using Rash analysis to aid the construction of preference-based measures from existing quality of life instruments. Poster presented at the Health Economics Study Group Meeting; 29 June-1 July 2005; University of Newcastle upon Tyne, UK
33. Yang Y, Tsuchiya A, Brazier J, Young TA. Estimating a preference-based single index from the Asthma Quality of Life Questionnaire (AQLQ). Poster presented at the Health Economists' Study Group Meeting, 5-7 January 2006; London, UK
34. Price D, Brown RE, Lloyd A. Burden of poorly controlled asthma for patients and society in the UK. Prim Care Resp J 2004;13:113
35. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72
36. Pharmaceutical Benefits Board. Price database for reimbursed drugs in Sweden [online]. Available from http://www.lfn.se/LFNTemplates/ ProductMedSearch_385.aspx [last accessed 15 September 2005]
37. Dewilde S, Rapatz G, Turk F. The cost of asthma exacerbations of different severity levels. Value in Health 2005;8:A31
38. Andersson F, Stahl E, Barnes PJ, et al. Adding formoterol to budesonide in moderate asthma - health economic results from the FACET study. Respir Med 2001;95:505-12
39. Henriksson F. Economic aspects of chronic diseases: multiple sclerosis and diabetes mellitus. Stockholm: Karolinska Institutet; 2001
40. The Swedish Association of Local Authorities and Regions. Cost per patient database (DRG 096) [online]. Available from http://sas.lf.se/kppprod/ index.htm [last accessed 23 February 2006]
41. Statistics Sweden. Wage statistics [online]. Available from http://www.scb.se/templates/publdb/publikation_2725. asp&plopnr=1525 [last accessed 23 February 2006]
42. Mattias E. Studies in health economics. Modelling and data analysis of costs and survival: Stockholm School of Economics; 2002
43. Lundberg L, Johannesson M, Isacson DGL, Borgquist L. Health state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Pub Health 1999;9: 211-7
44. Persson U, Hjelmgren J. Health services need knowledge of how the public values health. Lakartidningen 2003;100: 3436-7
45. Socialstyrelsen (National Board of Health and Welfare). The Swedish National Board of Health and Welfare's guidelines for cardiac care 2004: support for decisions in setting priorities [online]. Available from http://www.socialstyrelsen.se/Publicerat/2004/8511/2004-102-2.htm [last accessed 15 November 2005]
46. Miller AK, Zheng B, Fox H, et al. Significant association between previous and future asthma exacerbations in TENOR. Abstract presented at the American College of Allergy, Asthma and Immunology (ACAAI), 12-17 November 2004; Boston (MA)
47. Juniper EF, Svensson K, Mork AC, et al. Measuring health-related quality of life in adults during an acute asthma exacerbation. Chest 2004;125:93-7
48. Chipps B, Kim K, Korenblat P, et al. Effect of omalizumab on healthcare utilization in patients with moderate-to-severe allergic asthma. Poster presented at the American Academy of Allergic Asthma and Immunology, 7-12 March 2003; Denver (CO)
49. Israel E, Cohn JR, Meltzer EO, et al. Omalizumab does not induce thrombocytopenia in the treatment of asthma. Poster presented at the American Academy of Allergic Asthma and Immunology, 7-12 March 2003; Denver (CO)
50. Lane S, Molina J, Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir Med 2006;100:434-50
51. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with Etanercept or Infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10
52. Jobanputra P. HTA report: clinical effectiveness and cost effectiveness of new drug treatments for rheumatoid arthritis: Etanercept and Infliximab. 2001